

Lumakras (sotorasib)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

| MEMBER INFORMATION | |
|------------------------------|---------------------------------------|
| LAST NAME: | FIRST NAME: |
| PHONE NUMBER: | DATE OF BIRTH: |
| STREET ADDRESS: | |
| CITY: | STATE: ZIP CODE: |
| PATIENT INSURANCE ID NUMBER: | |

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

| PRESCRIBER INFORMATION | |
|---|---------------------------------------|
| LAST NAME: | FIRST NAME: |
| PRESCRIBER SPECIALTY: | EMAIL ADDRESS: |
| NPI NUMBER: | DEA NUMBER: |
| PHONE NUMBER: | FAX NUMBER: |
| STREET ADDRESS: | |
| CITY: | STATE: ZIP CODE: |
| REQUESTER (if different than prescriber): | OFFICE CONTACT PERSON: |

| MEDICATION OR MEDICAL DISPENSING INFORMATION | | | |
|--|----------------------------------|-------------------------------------|-----------|
| MEDICATION NAME: | | | |
| DOSE/STRENGTH: | FREQUENCY: | LENGTH OF THERAPY/REFILLS: | QUANTITY: |
| <input type="checkbox"/> NEW THERAPY | <input type="checkbox"/> RENEWAL | IF RENEWAL: DATE THERAPY INITIATED: | |
| DURATION OF THERAPY (SPECIFIC DATES): | | | |

Continued on next page

Lumakras (sotorasib)
Prior Authorization Request Form
 Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

| 1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? | | |
|--|--|---|
| <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO | | |
| MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): | DURATION OF THERAPY (SPECIFY DATES): | RESPONSE/REASON FOR FAILURE/ALLERGY: |
| 2. LIST DIAGNOSES: | | ICD-10: |
| <input type="checkbox"/> Locally advanced or metastatic non-small cell lung cancer(NSCLC) <input type="checkbox"/> Metastatic colorectal cancer <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): | | |
| 3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION. | | |
| Is patient going to be using drug in combination with a clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No | | |
| Is prescriber an oncologist/hematologist? <input type="checkbox"/> Yes <input type="checkbox"/> No | | |
| Does patient's NSCLC have the KRAS G12C-mutation? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation of mutation.</i> | | |
| <u>For diagnosis of advanced or metastatic non-small cell lung cancer(NSCLC), please answer the following:</u> | | |
| Did patient have disease progression after at least one prior systemic therapy including an immune checkpoint inhibitor (such as Keytruda®/pembrolizumab, Opdivo®/nivolumab, or Libtayo®/cemiplimab)? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> | | |
| Did patient have disease progression after at least one prior systemic therapy including platinum-based chemotherapy? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> | | |
| <u>For diagnosis of metastatic colorectal cancer, please answer the following:</u> | | |
| Has patient received at least 1 prior line of therapy for metastatic disease? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> | | |
| Has patient received and progressed or experienced disease recurrence on or after fluoropyrimidine, irinotecan, and oxaliplatin given for metastatic disease? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> | | |
| Is patient not a candidate for fluoropyrimidine, irinotecan, or oxaliplatin? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> | | |
| Does patient have an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2? <input type="checkbox"/> Yes <input type="checkbox"/> No | | |



Lumakras (sotorasib)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Renewal Request:

Is patient continuing to have a positive clinical response? Yes No *Please submit documentation.*

Is prescriber an oncologist/hematologist? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP-4201
P.O. Box 64811
St. Paul, MN 55164-0811
Phone: 877-228-7909